December 17, 2021 -- 20n Bio (20n), an artificial intelligence (AI)-powered drug discovery company focused on designing new proteins for therapeutics, has raised a $3.3 million in seed funding. 20n said it will use the proceeds to expand its scientific team, establish a discovery platform, and start multiple early studies in oncology and other genetic diseases.
Mingfu Zhu, PhD, founded the company in September 2021. Zhu has co-founded several AI-powered biotech companies in drug discovery and cancer diagnostics previously.
20n plans to quickly scale its current team of five full-time PhD-level employees and hire more scientists in computational protein design and RNA biology, the company said. Recently, 20n added two computational structural biologists to its scientific advisory board: Yaoqi Zhou, PhD, and Longxing Cao, PhD, who is a finalist of MIT's Technology Review Innovators Under 35 Asia Pacific 2021.
The funding was led by BlueRun Ventures China.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
